The firm is the first and only U.S. affiliate dedicated to the biotech investment of Mirae Asset, a prominent global financial group overseeing nearly $600bn AUM across a diversified platform, who has ...

Executives who work for health care and life sciences organizations typically make strategic decisions based on where they expect to get the best returns for their investments. This strategy has been ...

ARLINGTON, Va.--(BUSINESS WIRE)--Sands Capital, an active, long-term investor in leading innovative businesses globally, today announced the close of its third life sciences fund, Sands Capital Life ...

The capital infusion will support Serán’s continued growth with the build out of a new commercial-scale manufacturing facility that will be completed in 2026 Founded in 2016, Bain Capital Life ...

Fund focuses on achieving human clinical proof-of-concept for early stage drug development projects, following a capital efficient investment approach in collaboration with Lilly TVM Capital Life ...

Sands Capital has announced it has closed its third life sciences fund, Sands Capital Life Sciences Pulse Fund III, with $555 million. Through the new fund, the firm indicated it will continue to ...

Heart valve maker JenaValve Technology has raised $50 million in new venture capital funding, not long after receiving a breakthrough device designation from the FDA for its transcatheter aortic valve ...

Bain Capital Life Sciences (BCLS) has announced a new fund with approximately $3 billion in total commitments. The fourth fund for BCLS includes approximately $2.5 billion of outside commitments from ...

Fintel reports that Bain Capital Life Sciences Fund has filed a 13G/A form with the SEC disclosing ownership of 4.89MM shares of Annexon Inc (ANNX). This represents 9.99% of the company. In their ...